Search Our Scientific Publications & Authors

Aesthet Surg J 2019 Jan;39(Supplement_1):S14-S20

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a newly included provisional entity in the 2016 revision of the World Health Organization classification, is a distinct form of CD30-positive T-cell non-Hodgkin lymphoma that arises in association with a breast implant after reconstructive or cosmetic surgery. In addition to its characteristic clinical presentation, recent studies using next-generation sequencing have revealed that BIA-ALCL has a unique pattern of genetic alterations. BIA-ALCL is consistently negative for ALCL-related gene rearrangements involving ALK, DUSP22, and TP63. Read More

Chin Clin Oncol 2019 Jan 9. Epub 2019 Jan 9.

Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

Primary cutaneous CD30+ T cell lymphoproliferative disorders (pcCD30+ T cell LPDs) are a spectrum of pre-malignant to frankly neoplastic lymphoproliferations that comprise lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions. Although the atypical T cells that are the hallmark of these disorders share the expression of CD30, as the identifying marker, the clinical presentation, histological features and clinical course are vastly different. Furthermore, histopathologic features of pcCD30+ T cell LPDs may overlap with other cutaneous and systemic lymphomas. Read More

Eur J Dermatol 2019 Jan 21. Epub 2019 Jan 21.

Department of Pathology, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels.

Background: CD8+ CD30+ primary cutaneous T-cell lymphomas (PCTCL) are rare entities with overlapping pathological features and variable outcome.

Objectives: We sought to highlight the importance of correlation between pathological findings and clinical presentation for correct classification of the disease.

Material & Methods: Two cases of CD8+ CD30+ PCTCL were investigated. Read More

Dermatol Ther 2019 Jan 18:e12834. Epub 2019 Jan 18.

Department of Dermatology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.

Cutaneous CD30 lymphoproliferative disorders represent a spectrum of skin lymphatic reticular proliferative diseases, including lymphomatoid papulosis (LYP), primary cutaneous anaplastic large cell lymphoma (PC-ALCL), and borderline lesions between them. Although they all express CD30 as a phenotypic marker and share overlapping immunophenotypic features, they differ in clinical manifestations, pathological features, treatment, and prognosis. LYP is a kind of benign disease characterized by recurrent papules and nodules and may spontaneously regress. Read More

Haematologica 2019 Feb 10;104(2):226-235. Epub 2019 Jan 10.

Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid.

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Read More

Cancer Treat Res 2019 ;176:249-268

Division of Dermatology, City of Hope National Medical Center, Duarte, CA, USA.

Primary cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions [1]. CD30+ LPD are the second most common cutaneous T-cell lymphomas (CTCL) after mycosis fungoides (MF) and represent approximately 25% of all CTCL cases [2]. Their common phenotypic hallmark is an expression of the CD30 antigen, a cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily. Read More

Expert Rev Hematol 2019 Jan 18;12(1):5-19. Epub 2018 Dec 18.

a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Australia.

Introduction: Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. The utility of brentuximab vedotin has been explored in a number of diseases, with a recent focus on T-cell lymphoma, particularly systemic anaplastic large-cell lymphoma (sALCL) and cutaneous T-cell lymphoma (CTCL), as well as other peripheral T-cell lymphoma (PTCL) histologies. Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-cell lymphoma, as well as embedding it in a therapeutic context by reviewing potential competitor agents in the clinic. Read More

Chin Clin Oncol 2018 Oct 11. Epub 2018 Oct 11.

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

The term "CD30+ T-cell lymphoproliferative disorders" describes a group of diverse diseases of the skin, subcutaneous tissues and mucosa that range from lesions requiring clinical observation to those necessitating systemic cytotoxic chemotherapy. Careful consideration of both clinical and histopathologic presentation is needed for appropriate diagnosis and treatment. This review will present the current classification of these disorders and potential treatment paradigms. Read More

Am J Clin Dermatol 2019 Feb;20(1):115-122

University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1452, Houston, TX, 77030-4009, USA.

Cutaneous T-cell lymphomas (CTCLs) are a group of non-Hodgkin's lymphomas that present in the skin. In early-stage disease, the course is generally chronic and indolent; however, in advanced stages of disease, therapies rarely provide long-lasting responses, and the only potential curative therapy is allogeneic hematopoietic stem-cell transplantation. This has led to the search for novel targeted therapies to better treat more advanced stages of CTCLs that cannot be controlled by typical treatment regimens. Read More

Histopathology 2018 Nov 4. Epub 2018 Nov 4.

Aix-Marseille University, Marseille, France.

Aims: This study sought to clarify the molecular pathways underlying the putative evolution from lymphomatoid papulosis (LyP) to cutaneous anaplastic large-cell lymphoma (c-ALCL) and lymph node invasion (LNI).

Methods And Results: We analysed nine sequential tumours from the same patient presenting with parallel evolution of LyP (n = 3) and c-ALCL (n = 1) with LNI (n = 1), combined with systemic diffuse large B-cell lymphoma (DLBCL) (n = 4). Clonality analysis showed a common clonal T-cell origin in the five CD30+ lesions, and a common clonal B-cell origin in the four DLBCL relapses. Read More

Acta Dermatovenerol Croat 2018 Oct;26(3):264-266

Jaka Radoš, MD, University Hospital Centre Zagreb Department of Dermatology and Venereology School of Medicine University of Zagreb Šalata 4, 10000 Zagreb , Croatia;

Dear Editor,We present the case of a 40-year old male patient with lymphomatoid papulosis of a waxing and waning course on whom three biopsies were performed during a 14-year period with no change in histopathological or immunophenotypical characteristics. Lymphomatoid papulosis (LP) is a chronic, recurrent, self-healing papulonodular skin eruption with the histopathologic features of a cutaneous T-cell lymphoma but an often benign and indolent clinical course (1). It is designated as a primary, cutaneous, CD30+ lymphoproliferative disorder. Read More

Chin Clin Oncol 2018 Jul 19. Epub 2018 Jul 19.

Department of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421 Japan.

Primary cutaneous lymphoma is the second most common type of extranodal lymphoma. The clinical behavior of this lymphoma differs from that of other extranodal lymphomas and thus requires a particular pretreatment evaluation and treatment strategy. Cutaneous T-cell lymphoma (CTCL) accounts for 80% of primary cutaneous lymphoma cases and includes several confirmed disease entities as well as provisional entities. Read More

Open Access Maced J Med Sci 2018 Jul 12;6(7):1275-1277. Epub 2018 Jul 12.

Department of Dermatology, Venereology and Dermatologic Surgery, Medical Institute of Ministry of Interior (MVR-Sofia), General Skobelev 79, 1606 Sofia, Bulgaria.

Background: Modern drugs could sometimes be a good solution even to problematic patients. The cutaneous and systemic forms of the CD30 positive anaplastic large T-cell lymphoma could often be described as a suitable target for therapy with Brentuximab vedotin.

Case Report: We present the first case of a Bulgarian patient with a histologically confirmed primary cutaneous T-cell CD30+/ALK- large anaplastic cell lymphoma-cALCL (therapeutically resistant to therapy with Methotrexate, radiation therapy and systemic corticosteroid therapy) who was successfully treated with Brentuximab vedotin. Read More

Int J Dermatol 2018 Nov 3;57(11):1314-1319. Epub 2018 Aug 3.

Departments of Dermatology and Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.

Background: Little is currently known about health-related quality of life (HRQoL) of patients with cutaneous T-cell lymphoma (CTCL), a condition characterized by chronic, pruritic, visible lesions, features which may be uniquely influential.

Objective: The aim of this study was to establish baseline HRQoL data for patients with CTCL and identify its influencing factors.

Methods: Prospective, nonblinded survey design utilizing questionnaires including panels of QoL indices obtained from 105 patients with mycosis fungoides, Sezary syndrome, and CD30+ lymphoproliferative disorder. Read More

Postepy Dermatol Alergol 2018 Jun 18;35(3):274-279. Epub 2018 Jun 18.

Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland.

Introduction: Microbial infection and associated super antigens have been implicated in the pathogenesis of cutaneous T-cell lymphoma (CTCL), and many patients die from complicating bacterial infections. It has been postulated that () infection may be involved in the pathogenesis of (MF) but published data are limited and controversial.

Aim: To analyze the frequency of () DNA presence in blood samples of lymphoma cases. Read More

Br J Dermatol 2018 Dec 10;179(6):1400-1401. Epub 2018 Oct 10.

Department of Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' Hospitals, NHS Trust, London, U.K.

Am J Dermatopathol 2018 Jul;40(7):519-522

Department of Pathology, University of Virginia, Charlottesville, VA.

Anaplastic large-cell lymphoma (ALCL) was first described in 1985 by Stein et al and is a clinically, morphologically, and immunophenotypically heterogeneous neoplasm characterized by ALK expression, rearrangement of the ALK gene, and most characteristically its occurrence in children. Clinically, cutaneous ALK+ ALCL can be divided into primary (cutaneous forms) and the much more common, secondary dissemination by a systemic lymphoma. Systemic ALK+ ALCL represents 10%-15% of childhood non-Hodgkin lymphoma and generally presents with advanced systemic disease. Read More

Hautarzt 2018 Jun 7. Epub 2018 Jun 7.

Klinik für Dermatologie und Venerologie, Universitätsklinikum Freiburg, Freiburg, Deutschland.

Background: In addition to a broad and clinically diverse spectrum of known primary cutaneous lymphomas, for which an incidence of 1-3:100,000 is postulated, each year further entities are specified and defined. The goal is the presentation of a case series from daily clinical routine.

Methods: Over a period of 6 years and 2 months, patients consulting the Department of Dermatology, Medical Center University of Freiburg, were registered. Read More

J Cutan Pathol 2018 May 27. Epub 2018 May 27.

Section of Dermatopathology, Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Mycosis fungoides (MF) is the most common variant of cutaneous T-cell lymphomas. Large-cell transformation of MF has been associated with disease progression and overall poor outcome. The expression of CD30, which defines anaplastic large cell lymphoma (ALCL) and lymphomatoid papulosis, might also occur in a subset of patients with MF, with or without large-cell transformation. Read More

Semin Cutan Med Surg 2018 Mar;37(1):24-29

Department of Dermatology, University Medical Center, Göttingen, Germany.

Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ LPD) are the second most common form of cutaneous T-cell lymphoma. CD30+ LPD include lymphomatoid papulosis, primary cutaneous anaplastic large-cell lymphoma, and borderline lesions. Despite expression of CD30 by the neoplastic cells as the hallmark of these disorders, they differ in their clinical presentation and histological features as well as the course, the prognosis, and consecutively in the treatment. Read More

Actas Dermosifiliogr 2018 Sep 19;109(7):610-616. Epub 2018 Apr 19.

Servicio de Dermatología, Hospital Universitario 12 de Octubre, Institute i+12, Medical School. Universidad Complutense, ONCOCIBER, Madrid, España.

Background And Objective: Primary cutaneous lymphomas are uncommon. This article describes the Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV) and reports on the results from the first year.

Patients And Methods: Disease registry for patients with primary cutaneous lymphoma. Read More

Br J Haematol 2018 Jun 20;181(6):721-722. Epub 2018 Apr 20.

Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Ann Dermatol Venereol 2018 Jun - Jul;145(6-7):433-438. Epub 2018 Apr 17.

Service de dermatologie et d'allergologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France; Faculté de médecine, Sorbonne université, 75013 Paris, France. Electronic address:

Background: Fingolimod is an oral immunomodulator approved for relapsing-remitting multiple sclerosis. We report a case of a primary cutaneous CD30+ T-cell lymphoproliferation occurring 6 months after initiation of fingolimod. Based on a systematic literature review, the characteristics of these fingolimod-induced lymphoproliferative disorders are described. Read More

Cancers (Basel) 2018 Apr 4;10(4). Epub 2018 Apr 4.

Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, Eberhard-Karls-University, Liebermeisterstraße 8, 72076 Tübingen, Germany.

Anaplastic large cell lymphoma (ALCL) represents a group of malignant T-cell lymphoproliferations that share morphological and immunophenotypical features, namely strong CD30 expression and variable loss of T-cell markers, but differ in clinical presentation and prognosis. The recognition of anaplastic lymphoma kinase (ALK) fusion proteins as a result of chromosomal translocations or inversions was the starting point for the distinction of different subgroups of ALCL. According to their distinct clinical settings and molecular findings, the 2016 revised World Health Organization (WHO) classification recognizes four different entities: systemic ALK-positive ALCL (ALK+ ALCL), systemic ALK-negative ALCL (ALK− ALCL), primary cutaneous ALCL (pC-ALCL), and breast implant-associated ALCL (BI-ALCL), the latter included as a provisional entity. Read More

Acta Dermatovenerol Alp Pannonica Adriat 2018 03;27(1):33-34

Department of Dermatology, Dr. Vasantrao Pawar Medical College, Hospital & Research Center, Nashik, Maharashtra, India.

Primary cutaneous anaplastic large cell lymphoma is a CD30+ lymphoproliferative disorder of the skin characterized by the absence of nodal and visceral involvement, low recurrence rate, spontaneous remission, and tendency to occur in patients older than 20 years. The case presented here is of a 15-year-old boy with grouped papular lesions arranged in an annular fashion with a central clearing on his right arm for 4 months that was diagnosed with a case of anaplastic lymphoma kinase-negative primary cutaneous CD30+ anaplastic large cell lymphoma. The CT scan, bone marrow biopsy, and laboratory data ruled out systemic involvement. Read More

Curr Hematol Malig Rep 2018 04;13(2):135-141

Division of Hematology and Blood and Marrow Transplantation, Department of Medicine, University of California, San Francisco, 505 Parnassus Avenue, M1286, Box 0324, San Francisco, CA, 94143-0324, USA.

Purpose Of Review: Given the rarity of anaplastic large cell lymphoma (ALCL), studies evaluating new therapies have typically grouped ALCL together with other peripheral T cell lymphomas (PTCL). Thus, the treatment paradigm for ALCL largely mirrors that of PTCL in general. In this review, we discuss the current standard of care as well as emerging therapies, including antibody-based drugs, in systemic ALCL as well as primary cutaneous and breast implant-associated ALCL. Read More

Rinsho Ketsueki 2018;59(2):187-190

Department of Hematology, Tokyo Teishin Hospital.

We report a case of long-term administration of brentuximab vedotin (BV) for primary cutaneous anaplastic large cell lymphoma (pc-ALCL) with leukemic change. A 67-year-old man with lymphadenopathy was admitted to our hospital. Six years ago, he was diagnosed with pc-ALCL at another hospital, and complete remission was achieved with radiation therapy. Read More

J Invest Dermatol 2018 Aug 3;138(8):1795-1804. Epub 2018 Mar 3.

Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China. Electronic address:

Cutaneous CD30 lymphoproliferative disorders (LPDs), including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large-cell lymphoma, comprise the second most common group of cutaneous T-cell lymphomas. Previously, we reported that special SATB1, a thymocyte-specific chromatin organizer, was overexpressed and promoted malignant T-cell proliferation in a portion of CD30 LPDs. Here, we investigated the expression pattern of SATB1 in CD30 LPDs with a large cohort of patient samples, and examined the potential of SATB1 as a molecular marker to classify CD30 LPDs with differential clinicopathological behaviors. Read More

Open Access Maced J Med Sci 2018 Jan 13;6(1):137-138. Epub 2018 Jan 13.

"Onkoderma"- Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria.

Anaplastic large cell lymphoma (ALCL) represents an aggressive CD30 - positive T cell lymphoma, as it is the second most common T cell lymphoma and 2% to 5% of all non - Hodgkin lymphomas. The cutaneous involvement can be primary or secondary within systemic ALCL, resembling inflammatory and other neoplastic lesions both clinically and cytologically. Various pigmented cutaneous tumours with a different origin, cutaneous metastasis and B-cell lymphoma must be carefully considered in the differential diagnostic plan. Read More

Clin Exp Dermatol 2018 Jul 23;43(5):585-588. Epub 2018 Feb 23.

Department of Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Hospital Oberhausen, University Witten-Herdecke, Oberhausen, Germany.

CD30-positive primary cutaneous anaplastic large cell lymphoma (C-ALCL) is an indolent type of cutaneous lymphoma with favourable clinical prognosis. Pseudocarcinomatous hyperplasia (PCH) is a rare benign epithelial condition that can resemble invasive squamous cell carcinoma both clinically and histopathologically. PCH predominantly occurs in CD30-positive lymphoproliferative disorders. Read More

Br J Dermatol 2017 12;177(6):1474-1475

University Hospital Birmingham, Birmingham, U.K.

Case Rep Dermatol 2017 Sep-Dec;9(3):206-210. Epub 2017 Oct 20.

Department of Dermatology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.

CD30+ cutaneous anaplastic large-cell lymphoma is part of the CD30+ T-cell lymphoproliferative disorders. This type of lymphoma is in most cases indolent, with a high survival rate. We report the case of a 59-year-old patient with a 1-month lasting crusty lesion of the upper eyelid. Read More

J Invest Dermatol 2018 May 15;138(5):1126-1136. Epub 2017 Dec 15.

Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China; Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China. Electronic address:

Primary cutaneous anaplastic T-cell lymphoma, characterized by the CD30+ anaplastic large T cells, comprises the second most common group of cutaneous T-cell lymphoma. Little is known about the mechanisms of disease progression. Here we report that enhancer of zeste homolog 2 (EZH2), the catalytic subunit of polycomb repressive complex 2 that mediates histone H3 lysine 27 trimethylation, is overexpressed in CD30+ anaplastic cells in primary cutaneous anaplastic T-cell lymphoma and large-cell transformed cutaneous T-cell lymphoma. Read More

Mult Scler Relat Disord 2018 Jan 22;19:121-123. Epub 2017 Nov 22.

Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address:

Background: Previous reports of cutaneous neoplastic lesions secondary to Fingolimod treatment among multiple sclerosis patients.

Objective: Reporting a case of cutaneous large cell lymphoma in a multiple sclerosis patient during Fingolimod treatment.

Method: Case study. Read More

BMJ Case Rep 2017 Nov 4;2017. Epub 2017 Nov 4.

Scripps Clinic, Scripps Center for Organ Transplantation, La Jolla, California, USA.

Cutaneous T-cell post-transplant lymphoproliferative disorder (PTLD) is a rare clinical presentation that can potentially turn aggressive in solid-organ transplant recipients if not detected and intervened on early. We encountered a rare case of rapidly worsening primary cutaneous CD30-positive, Epstein-Barr virus-negative anaplastic large cell lymphoma (ALCL) of T-cell origin, manifesting as an isolated nasal tip lesion in a 71-year-old man 4 years after orthotopic liver transplantation. Excisional biopsy with partial rhinectomy showed subepithelial diffuse infiltration of medium-to-large lymphoid cells having round-to-irregular nuclei, partially condensed chromatin and prominent nucleoli. Read More

South Asian J Cancer 2017 Jul-Sep;6(3):129-131

Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 71103, USA.

Background: T-cell lymphomas with anaplastic morphology typically comprise of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL), ALK-negative ALCL (ALK- ALCL), and primary cutaneous ALCL (PC-ALCL). However, other entities such as diffuse large B-cell lymphoma, peripheral T-cell lymphoma, Hodgkin lymphoma, and undifferentiated carcinoma can also show similar anaplastic features.

Aims: To study the clinical features and histological spectrum of ALCL and emphasize the role of immunohistochemistry (IHC) in their diagnosis and categorization. Read More

Acta Derm Venereol 2018 01;98(1):123-125

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, PL-50-368 Wroclaw, Poland.

Blood Cancer J 2017 09 8;7(9):e603. Epub 2017 Sep 8.

Department of Haematology, Peter McCallum Cancer Centre, Melbourne, Victoria, Australia.

CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin lymphoma, among others. The variable expression of CD30 on both normal and malignant lymphoid cells has focused research efforts on understanding the pathogenesis of CD30 upregulation, its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. Read More

J Dtsch Dermatol Ges 2017 Sep 18;15(9):952-955. Epub 2017 Aug 18.

Department of Dermatology, Ludwigshafen City Hospital, Ludwigshafen am Rhein, Germany.

Int J Womens Dermatol 2017 Sep 11;3(3):140-144. Epub 2017 Jul 11.

Department of Dermatology, University of Connecticut Health Center, Farmington, CT.

One newly recognized form of T-cell lymphoma is breast implant-associated anaplastic large cell lymphoma (biALCL), which appears in close proximity to breast implants. The number of reported cases of biALCL is increasing and warrants careful attention by clinicians to more effectively diagnose and treat affected individuals. As pertinent to dermatologists, the objective of this paper is to present the associated cutaneous features of this clinical entity along with the pathogenesis, management, and clinical outcomes. Read More

Expert Opin Biol Ther 2017 12 28;17(12):1503-1510. Epub 2017 Aug 28.

a Unit of Dermatology, Department of Medicine , University of Padua , Padua , Italy.

Introduction: Cutaneous T-cell lymphomas (CTCLs) comprise of a group of rare and heterogeneous skin lymphoproliferative disorders derived from skin resident T cells. Treatment of CTCLs is based on skin-directed approaches and/or systemic therapies. Advanced CTCLs are difficult to treat with the currently available treatments as they generally fail to obtain prolonged clinical remission. Read More

Future Oncol 2017 Nov 14;13(27):2405-2411. Epub 2017 Aug 14.

Dermatology - University Hospitals Birmingham NHS Foundation Trust, University Hospital Birmingham, Birmingham, B15 2TH, UK.

CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin. CD30 binding allows internalization of BV inducing cell-cycle arrest and apoptosis. Read More

Int J Dermatol 2017 Dec 1;56(12):1400-1405. Epub 2017 Aug 1.

Department of Dermatology, University of Texas Southwestern, Dallas, TX, USA.

Background: The utility of brentuximab vedotin (BV) in CD30 systemic lymphomas is established, however evidence for treating primary cutaneous lymphoma remains limited. This study aimed to evaluate BV in treating CD30 transformed mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (PC-ALCL).

Methods: A literature review was conducted, and we analyzed data from published trials and case reports obtained via search of Ovid-MEDLINE and PubMed databases. Read More

J Cytol 2017 Jul-Sep;34(3):165-167

Department of Pathology, Seth GS Medical College and King Edward Memorial Hospital, Mumbai, Maharashtra, India.

Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma, accounting for <5% of non-Hodgkin's lymphoma. Cutaneous involvement can be primary or secondary arising in systemic ALCL. The diagnostic feature in both is the presence of pleomorphic, CD30 positive hallmark cells. Read More

Ann Diagn Pathol 2017 Jun 10;28:54-59. Epub 2017 Feb 10.

Department of Pathology and Laboratory Medicine, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY 10065, USA. Electronic address:

Background: Negative immunoregulatory checkpoints impede effective immune responses to tumor and reduce the action of anticancer agents. One such example is programmed death marker-1 (PD-1), an inhibitory signaling receptor expressed on activated and regulatory T-cells. PD-1 expression was reported in a few reports, but the expression profile of PD-1 and mycosis fungoides (MF) remains largely to be characterized. Read More

J Cutan Pathol 2017 Sep 18;44(9):772-775. Epub 2017 Jul 18.

Department of Dermatology, Los Angeles Medical Center (LAMC), Southern California Kaiser Permanente, Los Angeles, California.

Anaplastic large cell lymphoma (ALCL) is a CD30+ T-cell non-Hodgkin lymphoma with 2 main clinical presentations: primary cutaneous ALCL (pcALCL) and systemic ALCL (sALCL). While rare cases of myxoid sALCL have been reported, there are no previous cases of myxoid pcALCL reported. We present 2 unusual cases of pcALCL showing prominent collections of dermal mucin closely intermingling with the anaplastic lymphocytes. Read More

J Cutan Med Surg 2017 Nov/Dec;21(6):507-512. Epub 2017 Jun 14.

1 Division of Dermatology, University of Toronto, Toronto, ON, Canada.

Background: Lymphomatoid papulosis is one of the primary cutaneous CD30+ T-cell lymphoproliferative disorders. Although considered a benign disease, lymphomatoid papulosis has been associated potentially with an increased risk of secondary hematolymphoid malignancies.

Objective: The aim of this study was to assess the clinical characteristics and histologic subtypes of lymphomatoid papulosis, identify the prevalence and types of secondary hematolymphoid malignancies, and determine the potential risk factors for development of these hematolymphoid malignancies. Read More

Lancet 2017 08 7;390(10094):555-566. Epub 2017 Jun 7.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Cutaneous T-cell lymphomas are rare, generally incurable, and associated with reduced quality of life. Present systemic therapies rarely provide reliable and durable responses. We aimed to assess efficacy and safety of brentuximab vedotin versus conventional therapy for previously treated patients with CD30-positive cutaneous T-cell lymphomas. Read More